शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ABBOTINDIABSEAbbott India Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 12 Feb, 2026 · 13:33 IST

Unaudited Financial Results of the Company for the quarter ended December 31, 2025.

ABBOTINDIA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.3%Reaction day
₹26985.00
prior close
₹26670.00
announcement price
In-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.5%-0.8% vs market
Pharmaceuticals peers, median of 157sector-0.6%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
-0.3
15m
-0.2
30m
-0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.3-0.5-0.8-0.6-0.6
Next day
-1.8-2.1+0.3-1.4-0.4
2d
-2.5-1.7-0.8-2.1-0.4
3d
-1.1-1.5+0.3-1.6+0.5
4d
-1.8-0.9-0.9-1.6-0.2
5d
-2.1-2.5+0.3-2.5+0.3
1w
-2.1-2.2+0.1-2.9+0.9
15d
+1.2-5.3+6.5-6.5+7.7
1m
-1.3-7.0+5.8-6.6+5.4
2m
-4.8-5.3+0.5-3.3-1.4
3m
-0.1-1.8+1.7+0.9-1.0
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Abbott India reported Q3 FY26 revenue from operations of ₹1,724.04 Cr, up about 6.8% from ₹1,614.28 Cr in Q3 FY25. For nine months ended December 31, 2025, revenue grew to ₹5,219.54 Cr versus ₹4,804.56 Cr last year, an 8.6% increase. Net profit for the quarter was ₹375.96 Cr (vs ₹360.78 Cr, up ~4.2%), and for nine months it stood at ₹1,157.09 Cr (vs ₹1,047.40 Cr, up ~10.5%). Basic EPS for the quarter was ₹176.92. The company recognized a one-time incremental employee benefit cost of ₹35.10 Cr due to the New Labour Codes effective November 21, 2025, which pushed up employee expenses sharply. The statutory auditors (Walker Chandiok & Co LLP) issued an unqualified limited review report.

Likely market impact

Modest revenue and profit growth with margins slightly compressed in the quarter due to a one-time labour code charge; underlying business remains steady with double-digit profit growth on a nine-month basis, broadly neutral to mildly positive for shareholders.